Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,289.10 | 24.00 | 0.26% |
| CAC 40 | 8,401.18 | 81.31 | 0.98% |
| DAX 40 | 26,569.99 | 202.75 | 0.77% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,388.87 | 195.92 | -0.77% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 65,361.60 | 1,043.96 | -1.57% |
| NZX 50 Index | 13,869.89 | 101.71 | 0.74% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,095.10 | 29.50 | 0.33% |
| SSE Composite Index | 3,941.59 | 10.59 | -0.27% |